ARTARA THERAPEUTICS develops targeted therapeutic solutions for chronic diseases through advanced drug formulation and delivery systems. The company focuses on improving patient outcomes by enhancing the efficacy and accessibility of treatment options in the healthcare sector.
Funding
$100M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many patients on parenteral support (PS) experience choline deficiency, leading to potential liver damage. Current treatment options lack FDA-approved intravenous (IV) choline formulations, creating a gap in care for these patients. Additionally, effective treatments for oncologic indications and lymphatic malformations (LMs) often have limitations in efficacy and accessibility.
Solution
Protara Therapeutics is developing targeted therapies to address unmet needs in patients with cancer and those requiring parenteral support. Their lead investigational cell therapy, TARA-002, leverages the immunopotentiator OK-432, already approved in Japan and Taiwan for certain oncologic indications and LMs. Protara is evaluating TARA-002 for non-muscle invasive bladder cancer (NMIBC) and LMs in the U.S. They are also developing IV Choline Chloride, an investigational phospholipid substrate replacement therapy, with the potential to be the first FDA-approved IV choline formulation for PS patients, addressing choline deficiency and associated liver damage.
Target Audience
The primary target audience includes patients with non-muscle invasive bladder cancer (NMIBC), lymphatic malformations (LMs), and individuals on parenteral support (PS) who are at risk of choline deficiency and associated liver damage, as well as the healthcare providers who treat them.
Features
- TARA-002: Cell therapy based on OK-432, an immunopotentiator approved in Japan and Taiwan for oncologic indications and lymphatic malformations.
- Investigational treatment for non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs) in the U.S.
- IV Choline Chloride: Investigational phospholipid substrate replacement therapy for patients on parenteral support (PS).
- Aims to address choline deficiency, which affects approximately 80% of PS patients and can lead to liver damage.
- Potential to be the first FDA-approved IV choline formulation for PS patients.
- Granted Rare Pediatric Disease Designation by the U.S. Food and Drug Administration for TARA-002.